Vivek G. Patel, MD, discusses the potential advantages of subcutaneous bispecific antibodies that are being evaluated in frontline follicular lymphoma.
Vivek G Patel, MD
Advertisement
Vivek G Patel, MD, is an assistant professor of medicine in the Division of Hematology Oncology at Vanderbilt University Medical Center.
Articles by Vivek G Patel, MD
Vivek G. Patel, MD, discusses the safety profile of bispecific antibodies for the treatment of patients with follicular lymphoma.
Vivek G Patel, MD, discusses the comparative efficacy and safety profiles of mosunetuzumab and epcoritamab in follicular lymphoma.
Advertisement
Latest Updated Articles
Dr Patel on Choosing Between Mosunetuzumab and Epcoritamab in Follicular LymphomaPublished: May 2nd 2025 | Updated: May 2nd 2025
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma
5